Develops antibody-drug conjugates for colorectal cancer.
Jun 2026Revenue $18.3M/yrExpenses $105M/yr
No trendCash runway ≈ 4.0 years from Jun 2026
Figures by year
When will CytomX Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $18.3M and expenses $105M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $76.2M | $98.6M | −$22.4M |
| Dec 2024 | $138M | $113M | $25.0M |
| Dec 2023 | $101M | $108M | −$6.48M |
| Dec 2022 | $53.2M | $154M | −$101M |
| Dec 2021 | $37.3M | $153M | −$116M |
| Dec 2020 | $68.4M | $149M | −$80.5M |
| Dec 2019 | $26.9M | $168M | −$141M |
| Dec 2018 | $59.5M | $137M | −$77.9M |
| Dec 2017 | $71.6M | $118M | −$46.3M |
| Dec 2016 | $15.0M | $74.6M | −$59.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.